Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398429 | 0.91 | S1PR1 (0.63) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398520 | 0.89 | S1PR1 (0.76) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL400699 | 0.88 | S1PR1 (0.61) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398612 | 0.84 | S1PR1 (0.81) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398479 | 0.84 | S1PR1 (0.61) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL3310448 | 0.83 | S1PR1 (0.48) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL13361389 | 0.82 | S1PR1 (0.54) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398450 | 0.82 | S1PR1 (0.62) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL1398472 | 0.82 | S1PR1 (0.65) | S1PR1CYP2C9S1PR3 | |
| SCHEMBL13332369 | 0.81 | S1PR1 (0.55) | S1PR1CYP2C9S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-8324254-B2 | Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists | GLAXO GROUP LIMITED (GB) | 2012-12-04 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | GLAXO GROUP LIMITED | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113528-A1 | OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885CYP2C9 3130/4885S1PR3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.